NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”
or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth
quarter 2018 financial results on or before April 4, 2019 and host a conference call on Thursday, April 4, 2019 at 4:30 p.m.
Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business
update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s
Chief Financial Officer, will discuss fourth quarter 2018 financial results.
To access the conference call, U.S.-based listeners should dial (877) 407-3982 and international listeners
should dial (201) 493-6780. All listeners should provide the operator with the conference call name “PAVmed, Inc. Business Update
Conference Call” to join. Individuals interested in listening to the live conference call via webcast may do so by visiting the
investor relations section of the Company’s website at www.pavmed.com.
Following the conclusion of the conference call, a replay will be available for one week and can be accessed by
dialing (844) 512-2921 from within the U.S. or (412) 317-6671 from outside the U.S. To access the replay, all listeners should
provide the following pin number: 13688196. The webcast will be available for replay on the investor relations section of the
Company’s website at www.pavmed.com.
About PAVmed
PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model
designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical
medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and
accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs encompassing a broad spectrum
of clinical areas with attractive regulatory pathways and market opportunities. Its five lead products provide groundbreaking
approaches to carpal tunnel syndrome (CarpX™), precancerous conditions of the esophagus (EsoCheck™), vascular access (PortIO™),
pediatric ear infections (DisappEAR™) and medical infusions (NextFlo™). The company is also developing innovative products in other
areas, such as catheters and tissue ablation, while seeking to further expand its pipeline through engagements with clinician
innovators and leading academic medical centers. For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking
statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and
expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, factors affecting
the timing and effectiveness of the registration statement for our proposed rights offering; volatility in the price of PAVmed’s
common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required advance PAVmed’s products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and results from PAVmed’s preclinical studies; whether and when
PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s products once cleared and commercialized;
our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or
other regulatory body to market any of its products. New risks and uncertainties may arise from time to time and are difficult to
predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. For a
further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see
Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Reports on Form 10-Q filed by PAVmed
after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking
statements.
Contacts:
Investors
Mike Havrilla
Director of Investor Relations
(814) 241-4138
JMH@PAVmed.com
Media
Shaun O’Neil
Chief Commercial Officer
(518) 812-3087
SMO@PAVmed.com
